Steward Partners Investment Advisory LLC Purchases 431 Shares of Illumina, Inc. (NASDAQ:ILMN)

Steward Partners Investment Advisory LLC raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 57.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,182 shares of the life sciences company’s stock after acquiring an additional 431 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Illumina were worth $158,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of ILMN. Versant Capital Management Inc boosted its position in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC bought a new stake in Illumina during the 4th quarter valued at approximately $32,000. TD Private Client Wealth LLC boosted its position in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after acquiring an additional 141 shares in the last quarter. V Square Quantitative Management LLC boosted its position in shares of Illumina by 50.6% in the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 132 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its position in shares of Illumina by 73.5% in the 4th quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock worth $59,000 after purchasing an additional 186 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of ILMN opened at $85.60 on Monday. The firm has a market cap of $13.56 billion, a PE ratio of -11.15, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The firm has a fifty day simple moving average of $113.52 and a two-hundred day simple moving average of $129.86. Illumina, Inc. has a 1-year low of $80.18 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ILMN. Morgan Stanley dropped their price target on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and dropped their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Canaccord Genuity Group dropped their price target on Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, March 11th. HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research report on Friday, February 28th. Finally, Royal Bank of Canada dropped their price target on Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 12th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.